Tests an artery-delivered protective treatment for ischemic stroke patients
Explores safety and feasibility of artery-delivered protective drugs in adults with acute ischemic stroke.
Plain-language title generated from the registry record
Registry title: Intra-arterial Neuroprotective Strategy for Ischemic STroke Patients With No Reperfusion Therapy (INSIST-NRT)
Key facts
- Where
- Shenyang, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with an acute ischemic stroke who did not get clot-opening treatment, or whose stroke got worse within 48 hours. It tests a drug given into an artery to protect the brain.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Major stroke symptoms, with an NIHSS score from 6 to 20. Before the stroke, the person was fully independent or nearly so (mRS 0 or 1).
- Earlier treatment
- Missed clot-opening treatment (IVT or EVT), or the stroke got worse within 48 hours (NIHSS rose by more than 4). People who had IVT or EVT cannot join.
Main reasons for not taking part
- Modified Rankin Score above 2 from an earlier stroke
- Had intravenous thrombolysis or endovascular treatment
- Blood clotting problems, bleeding tendency or low platelets (below 80000/mm3)
- Severe liver or kidney problems, or needing dialysis
- Very high blood pressure (above 200 mmHg systolic or 110 mmHg diastolic)
Read by machine on 9 November 2026.
Where in China
- Department of Neurology, General Hospital of Northern Theater CommandShenyang, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Hui-Sheng Chen
- Trial code
- NCT04664946
- Record updated
- 10 September 2026
- Original description
To explore the safety and feasibility of intra-arterial neuroprotective strategy in acute ischemic stroke patients who missed recanalization operation.Read full original descriptionShow less
Intra-arterial Neuroprotective Strategy for Ischemic STroke Patients With No Reperfusion Therapy (INSIST-NRT): One Single Center, Safety and Feasibility Study
To explore the safety and feasibility of intra-arterial neuroprotective strategy in acute ischemic stroke patients who missed recanalization operation.
Inclusion: Age ≥18 years; Major neurologic deficits: 6≤NIHSS≤20; Missing recanalization therapy (IVT or EVT) or progressive stroke, which was defined as symptoms worsen in 48 hours (an increase in NIHSS more than 4); Premorbid mRS 0 or 1; Signed informed consent.
Exclusion: Modified Rankin Score >2 caused by a history of prior stroke; Coagulation disorders, systematic hemorrhagic tendency, thrombocytopenia （ <80000/mm3; Severe hypertension (systolic blood pressure over 200mmHg or diastolic blood pressure over 110 mmHg); Severe hepatic or renal dysfunction, increase in ALT or AST (more than 2 times of upper limit of normal value), increase in serum creatinine (more than 1.5 times of upper limit of normal value) or requiring dialysis; Patients who underwent intravenous thrombolysis or Endovascular treatment; Unsuitable for this clinical studies assessed by researcher.